RLAYNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Relay Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$17.09+0.81 (+4.98%)
Close on Oct 19, 2026
- Market cap
- $3.47B
- P/E (TTM)
- –
- Dividend yield
- –
Relay Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Relay Therapeutics | Industry median |
|---|---|---|
| Market Cap | $3.75B | $197.05M |
| Enterprise Value | $3.62B | $106.56M |
| PS Ratio | 361.85 | 3.93 |
| PB Ratio | 4.21 | 2.14 |
| P/TBV Ratio | 4.21 | 2.46 |
Enterprise value
| Measure | Relay Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 350.14 | 2.69 |
Income (trailing twelve months)
| Measure | Relay Therapeutics | Industry median |
|---|---|---|
| Revenue | $10.35M | $57.94M |
| Operating Income | -$310.44M | -$21.44M |
| Net Income | -$286.04M | -$22.46M |
| EBITDA | -$310.44M | -$16.91M |
| EPS (Diluted) | -$1.57 | -$0.83 |
Margins
| Measure | Relay Therapeutics | Industry median |
|---|---|---|
| Operating Margin | -2999.4% | -44.5% |
| Profit Margin | -2763.6% | -39.2% |
| EBITDA Margin | -2999.4% | -31.3% |
Returns
| Measure | Relay Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -36.8% | -53.1% |
| Return on Assets (ROA) | -33.7% | -41.0% |
| Return on Invested Capital (ROIC) | -37.1% | -32.0% |
| Return on Capital Employed (ROCE) | -33.9% | -37.8% |
Growth
| Measure | Relay Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 23.9% | 6.01% |
| Revenue Growth (3Y CAGR) | 123.2% | 2.25% |
| Revenue Growth (5Y CAGR) | -28.6% | 6.42% |
Balance sheet
| Measure | Relay Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $121.19M | $62.42M |
| Net Cash (Debt) | $121.19M | $15.68M |
| Net Cash Per Share | $0.55 | $0.65 |
| Equity (Book Value) | $890.01M | $48.79M |
| Book Value Per Share | $4.06 | $1.36 |
| Tangible Book Value | $890.01M | $23.06M |
| Working Capital | $877.28M | $75.77M |
Financial position
| Measure | Relay Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 18.27 | 3.30 |
| Quick Ratio | 2.39 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Relay Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$212.21M | -$12.35M |
Efficiency
| Measure | Relay Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.01 | 0.38 |
| Revenue Per Employee | $53.91K | $398.96K |
| Profits Per Employee | -$1.49M | -$732.08K |
| Employee Count | 192 | 73 |
Dividends and yields
| Measure | Relay Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -7.64% | -21.2% |
Shares
| Measure | Relay Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 219,142,000 | 59,128,900 |
| Shares Change (YoY) | 12.4% | 11.1% |
| Shares Change (QoQ) | 15.5% | 0.54% |
| Float | 165,485,000 | 48,744,500 |
| Shares Held by Insiders | 24.5% | 11.8% |
| Shares Held by Institutions | 112.6% | 59.4% |
Scores
| Measure | Relay Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 25.91 | 0.10 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Relay Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.